CD19 and colitis: After PL8177 treatment the relative number of enterocytes were increased and the proportion of T and Cd19+ B cells were reduced in comparison to animals on placebo, in agreement with the improvement of the markers of colitis observed with the other histologic measures (colon weight reduction, stool consistency, and fecal occult blood score).